|
Abu Dhabi reinforces
global leadership in
healthcare innovation with
high-level U.S. visit
(ABU DHABI)
-
A high-level
delegation led by the
Department of Health – Abu
Dhabi (DoH) is set to
embark on a strategic
mission to the United States
from June 14 to 21, 2025.
The visit reaffirms Abu
Dhabi’s global leadership in
healthcare innovation and
reflects its broader vision
for healthcare
transformation, driven by
innovation, investment, and
a deep commitment to
international collaboration.
The delegation will
visit key U.S. cities,
including Boston, Washington
D.C., and Philadelphia, in
parallel with Abu Dhabi’s
participation at
BIO International Convention
2025, one of the world’s
foremost biotechnology
events. The visit will
spotlight the Emirate’s
achievements in AI, digital
health, genomics, and
clinical research and
showcase Abu Dhabi’s Health,
Endurance, Longevity, and
Medicine (HELM) Life Science
Cluster, while promoting
long-term strategic
partnerships with government
entities, research
institutions, and global
innovators.
H.E. Dr. Noura Khamis Al
Ghaithi, Undersecretary of
the Department of Health –
Abu Dhabi, stated:
“This mission reflects our
commitment to shaping the
future of health through
collaboration, innovation,
and shared purpose. Our
vision is to build a health
system that predicts,
prevents, acts to restore,
and acts to cure, therefore
ensuring better outcomes for
our communities and beyond.
This can only be achieved
through meaningful
partnerships and a shared
ambition to improve lives.
We are proud to join our
partners in the United
States to explore new
opportunities that advance
healthcare, both in the UAE
and globally.”
The
delegation will conduct over
20 strategic meetings and
visits with public and
private sector leaders
across the U.S., aimed at
knowledge exchange,
investment opportunities,
and the signing of new
agreements that accelerate
the adoption of advanced
health solutions.
Representing Abu Dhabi’s
innovation ecosystem, the
delegation includes key
stakeholders such as the Abu
Dhabi Investment Office,
Mubadala BIO, M42, Masdar
City, KEZAD, PureHealth, and
Etihad Cargo.
Abu
Dhabi continues to lead the
region in genomics through
the Emirati Genome Program,
which has successfully
sequenced over 800,000
samples, creating one of the
most advanced national
genomic databases. The
Emirate is also home to more
than 90 licensed research
centers and 30+ ongoing
clinical trials in areas
such as oncology, rare
diseases, and chronic
conditions. Advanced data
platforms such as Malaffi,
which securely store over 5
million patient records,
enable AI-powered insights
and real-world evidence,
while national initiatives
like the Golden Visa program
are cultivating a global
workforce and have granted
over 2,000 long-term visas
for researchers and
healthcare professionals
from around the world.
PRINT
THIS ARTICLE
|
